Background
==========

To develop new approaches for the targeted deletion of pathogenic autoimmune B lymphocytes, we have studied a bacterial product, protein A of *Staphylococcus aureus*(SpA). We have previously discovered that SpA has the properties of a B-cell superantigen, enabling interactions with conserved variable region framework subdomains of the antigen receptors of lymphocytes rather than the complementarity determining region involved in the binding of conventional antigens \[[@B1]\]. Exposure to SpA can induce immune tolerance affecting a supraclonal set of lymphocytes \[[@B2]\].

Objective
=========

To evaluate the outcome of *in vivo*SpA treatment.

Results
=======

Within hours, a sequence of events is initiated only in targeted B cells, with rapid downregulation of B-cell antigen receptor and the coreceptors CD19 and CD21, the induction of an activation phenotype, and limited rounds of proliferation. Massive B-cell-specific apoptosis then occurs through a process heralded by the dissipation of mitochondrial membrane potential, followed later by the induction of the caspase pathway and DNA fragmentation. Post exposure, B-cell apoptotic bodies are deposited in the spleen, the lymph nodes and Peyers patches. While *in vivo*apoptosis does not require a death receptor, such as Fas, recent studies have demonstrated that apoptosis is linked to an induced imbalance in the members of the Bcl-2 family. By microfluorimetry and deconvoluted confocal microscopy, SpA induced a rapid depletion of Bcl-XL. There was also increased expression and translocation of a pro-apoptotic BH3-only member, which can form heterodimers resulting in Bax/Bak-mediated death.
